Shares of Abeona Therapeutics Inc (NASDAQ:ABEO) have been assigned an average rating of “Buy” from the twelve research firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $28.50.
A number of research analysts have commented on ABEO shares. Zacks Investment Research upgraded Abeona Therapeutics from a “sell” rating to a “buy” rating and set a $18.00 price objective on the stock in a research note on Wednesday, November 22nd. SunTrust Banks started coverage on Abeona Therapeutics in a research note on Wednesday, November 8th. They set a “buy” rating and a $26.00 price objective on the stock. Maxim Group set a $35.00 price target on Abeona Therapeutics and gave the stock a “buy” rating in a research note on Monday, November 20th. Royal Bank of Canada started coverage on Abeona Therapeutics in a research note on Thursday, September 14th. They issued an “outperform” rating and a $23.00 price target on the stock. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $21.00 price target on shares of Abeona Therapeutics in a research note on Friday, October 6th.
Several large investors have recently added to or reduced their stakes in the stock. State of Wisconsin Investment Board acquired a new stake in Abeona Therapeutics during the second quarter valued at approximately $122,000. Rhumbline Advisers acquired a new stake in Abeona Therapeutics during the second quarter valued at approximately $190,000. Schwab Charles Investment Management Inc. acquired a new stake in Abeona Therapeutics during the second quarter valued at approximately $264,000. California State Teachers Retirement System acquired a new stake in Abeona Therapeutics during the second quarter valued at approximately $275,000. Finally, Teachers Advisors LLC acquired a new stake in Abeona Therapeutics during the second quarter valued at approximately $284,000. Institutional investors and hedge funds own 41.95% of the company’s stock.
Shares of Abeona Therapeutics (NASDAQ:ABEO) traded down $0.15 on Friday, hitting $14.95. The company’s stock had a trading volume of 435,100 shares, compared to its average volume of 644,313. Abeona Therapeutics has a 12 month low of $4.25 and a 12 month high of $22.75.
Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings data on Wednesday, November 15th. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.05. The company had revenue of $0.22 million for the quarter, compared to analysts’ expectations of $0.22 million. Abeona Therapeutics had a negative return on equity of 27.69% and a negative net margin of 2,946.58%. sell-side analysts expect that Abeona Therapeutics will post -0.6 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This article was posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://www.thelincolnianonline.com/2018/01/14/abeona-therapeutics-inc-abeo-given-average-recommendation-of-buy-by-analysts-updated-updated-updated.html.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.